Evidence map›Paper›PMID 40298556›Full record

ArticleAntibiotics (Basel, Switzerland)2025

Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium-Severe Clostridioides Difficile Infection.

Jasna Rahimić, Ervin Alibegović, Lana Lekić, Marijana Marković Boras, Amina Džidić-Krivić, Esma Karahmet Farhat, Emina Karahmet Sher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jasna RahimićFaculty of Medicine, European University Kallos, Tuzla, XVIII Hrvatske Brigade 8, 75000 Tuzla, Bosnia and Herzegovina.
Ervin AlibegovićDepartment of Clinical Center, Tuzla University, 75000 Tuzla, Bosnia and Herzegovina.
Lana LekićFaculty of Health Studies, University of Sarajevo, Stjepana Tomića 1, 71000 Sarajevo, Bosnia and Herzegovina.
Marijana Marković BorasInternational Society of Engineering Science and Technology UK, Nottingham NG7 1GN, UK.
Amina Džidić-KrivićInternational Society of Engineering Science and Technology UK, Nottingham NG7 1GN, UK.
Esma Karahmet FarhatFaculty of Food Technology, Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
Emina Karahmet SherInternational Society of Engineering Science and Technology UK, Nottingham NG7 1GN, UK.ORCID 0000-0002-0913-5759

Funding

King Saud University RSP2025 R169
6 · The paper itself

Abstract

backgroundAll currently used therapeutic protocols and drugs for

objectivesTo compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + nifuroxazide as a therapeutic protocol for a medium-severe form of CDI. In addition, the effects of a modified therapeutic protocol with standard monotherapy on the number of stools and stool consistency in a medium-severe CDI will be compared. MATERIALS AND

methodsA prospective, randomized, controlled clinical trial that included 60 patients divided into two groups was conducted. One group of patients was treated with vancomycin monotherapy. The other group was treated with the modified therapeutic protocol (vancomycin + nifuroxazide).

resultsThe modified therapy with vancomycin + nifuroxazide demonstrated enhanced pharmacological efficacy in the management of CDI compared to the standard vancomycin monotherapy. Patients treated with dual therapy reported a significantly lower number of stools in first, second and third control; first control (4.47 ± 2.20 compared to 5.70 ± 1.91 in vancomycin group (

conclusionsNifuroxazide and vancomycin have demonstrated accelerated improvement in patient status and hold promise as a novel dual therapeutic regimen for managing patients diagnosed with a medium-severe form of CDI.

Indexed as

Clostridioides difficile infection (CDI)modified therapeutic protocolnifuroxazide and dual antibiotic therapyvancomycin

Identifiers

PMID40298556
PMCPMC12024110

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.